Immupharma Plc Stock Fundamentals
| IMM Stock | 1.57 0.02 1.26% |
ImmuPharma PLC fundamentals help investors to digest information that contributes to ImmuPharma PLC's financial success or failures. It also enables traders to predict the movement of ImmuPharma Stock. The fundamental analysis module provides a way to measure ImmuPharma PLC's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to ImmuPharma PLC stock.
At present, ImmuPharma PLC's Other Operating Expenses is projected to increase significantly based on the last few years of reporting. The current year's Total Operating Expenses is expected to grow to about 5.1 M, whereas Interest Expense is forecasted to decline to 1,887. ImmuPharma | Select Account or Indicator |
ImmuPharma PLC Company Operating Margin Analysis
ImmuPharma PLC's Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current ImmuPharma PLC Operating Margin | 36.15 % |
Most of ImmuPharma PLC's fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, ImmuPharma PLC is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
| Competition |
Based on the recorded statements, ImmuPharma PLC has an Operating Margin of 36.1472%. This is much higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The operating margin for all United Kingdom stocks is notably lower than that of the firm.
ImmuPharma PLC Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining ImmuPharma PLC's current stock value. Our valuation model uses many indicators to compare ImmuPharma PLC value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across ImmuPharma PLC competition to find correlations between indicators driving ImmuPharma PLC's intrinsic value. More Info.ImmuPharma PLC is currently regarded as number one stock in return on equity category among its peers. It also is currently regarded as number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the ImmuPharma PLC's earnings, one of the primary drivers of an investment's value.ImmuPharma Operating Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ImmuPharma PLC's direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ImmuPharma PLC could also be used in its relative valuation, which is a method of valuing ImmuPharma PLC by comparing valuation metrics of similar companies.ImmuPharma PLC is currently under evaluation in operating margin category among its peers.
ImmuPharma Fundamentals
| Return On Equity | -1.11 | ||||
| Return On Asset | -0.43 | ||||
| Operating Margin | 36.15 % | ||||
| Current Valuation | 6.31 M | ||||
| Shares Outstanding | 416.44 M | ||||
| Shares Owned By Insiders | 48.33 % | ||||
| Shares Owned By Institutions | 17.44 % | ||||
| Price To Book | 2.42 X | ||||
| Price To Sales | 60.75 X | ||||
| Gross Profit | 118.35 K | ||||
| EBITDA | (3.03 M) | ||||
| Net Income | (2.92 M) | ||||
| Total Debt | 1.67 M | ||||
| Book Value Per Share | 0.01 X | ||||
| Cash Flow From Operations | (1.36 M) | ||||
| Earnings Per Share | (0.01) X | ||||
| Target Price | 5.0 | ||||
| Beta | 1.58 | ||||
| Market Capitalization | 6.54 M | ||||
| Total Asset | 2.72 M | ||||
| Retained Earnings | (64.08 M) | ||||
| Working Capital | (321.92 K) | ||||
| Net Asset | 2.72 M |
About ImmuPharma PLC Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ImmuPharma PLC's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ImmuPharma PLC using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ImmuPharma PLC based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | -437.1 K | -458.9 K | |
| Cost Of Revenue | 37.6 K | 35.7 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in ImmuPharma Stock
ImmuPharma PLC financial ratios help investors to determine whether ImmuPharma Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in ImmuPharma with respect to the benefits of owning ImmuPharma PLC security.